US equities |
MU $904.90 ▲+0.00% SNDK $1,371.12 ▲+0.00% NVDA $217.09 ▲+0.00% SPCX $147.96 ▲+0.00% SKHY $142.87 ▲+0.00% TSLA $368.06 ▲+0.00% AAPL $342.94 ▲+0.00% CRWV $61.12 ▲+0.00%
FinancialContent

Articles published by MapLight Therapeutics, Inc.

News headline image
MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics
From MapLight Therapeutics, Inc.
Via GlobeNewswire
Tickers MPLT
News headline image
MapLight Therapeutics to Participate in Upcoming Investor Conference
From MapLight Therapeutics, Inc.
Via GlobeNewswire
Tickers MPLT
News headline image
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
From MapLight Therapeutics, Inc.
Via GlobeNewswire
Tickers MPLT
News headline image
MapLight Therapeutics Announces $150 Million Private Placement Financing
From MapLight Therapeutics, Inc.
Via GlobeNewswire
Tickers MPLT
News headline image
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
From MapLight Therapeutics, Inc.
Via GlobeNewswire
Tickers MPLT
News headline image
MapLight Therapeutics Announces Changes to Board of Directors
From MapLight Therapeutics, Inc.
Via GlobeNewswire
Tickers MPLT
News headline image
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
From MapLight Therapeutics, Inc.
Via GlobeNewswire
Tickers MPLT
News headline image
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
From MapLight Therapeutics, Inc.
Via GlobeNewswire
Tickers MPLT
News headline image
MapLight Therapeutics to Participate in Upcoming Investor Conferences
From MapLight Therapeutics, Inc.
Via GlobeNewswire
Tickers MPLT
News headline image
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
From MapLight Therapeutics, Inc.
Via GlobeNewswire
Tickers MPLT
News headline image
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From MapLight Therapeutics, Inc.
Via GlobeNewswire
Tickers MPLT
News headline image
MapLight Therapeutics to Participate in Upcoming Investor Conferences
From MapLight Therapeutics, Inc.
Via GlobeNewswire
Tickers MPLT
News headline image
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
From MapLight Therapeutics, Inc.
Via GlobeNewswire
Tickers MPLT
News headline image
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis
From MapLight Therapeutics, Inc.
Via GlobeNewswire
Tickers MPLT
News headline image
SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies
From MapLight Therapeutics, Inc.
Via GlobeNewswire
Tickers MPLT
News headline image
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
From MapLight Therapeutics, Inc.
Via GlobeNewswire
Tickers MPLT
News headline image
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From MapLight Therapeutics, Inc.
Via GlobeNewswire
Tickers MPLT
News headline image
MapLight Therapeutics Announces Pricing of Initial Public Offering
From MapLight Therapeutics, Inc.
Via GlobeNewswire